Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade

Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade

Background Immune checkpoint inhibitors (ICIs) are the preferred systemic therapy for most patients with advanced Merkel cell carcinoma (MCC). However, the optimal duration of treatment for patients responding to ICI is unclear. Emerging data from retrospective analyses indicate a higher risk of MCC...

Full description

Saved in:
Bibliographic Details
Main Authors: Shailender Bhatia, Daniel S Hippe, Paul T Nghiem, Candice Church, Tomoko Akaike, Kristina Lachance, Lisa Tachiki, Thomas Pulliam, Song Y Park, Coley Doolittle-Amieva, Lisa Zaba, Nora A Alexander, Emily Gong, Lauren Zawacki, Allison J Remington, Yasman Moshiri, Alex Fu, Emily Huynh, Nikhil Harikrishnan, Marika Bierma
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e012123.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/8/e012123.full

Similar Items